Rating Buzzer: Is Aegis Capital Positive On Globus Medical (GMED)?

November 30, 2016 - By Darrin Black

Rating Buzzer: Is Aegis Capital Positive On Globus Medical (GMED)?

How Aegis Capital Rates Globus Medical (GMED)

Equities researchers at Aegis Capital has begun coverage on shares of Globus Medical (GMED) in a research report revealed to investors on Wednesday, 30 November, Octafinance.com reports. The financial firm set Buy rating on GMED stock.

Globus Medical Inc (NYSE:GMED) Ratings Coverage

Out of 2 analysts covering Globus Medical (GMED), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Globus Medical has been the topic of 2 analyst reports since November 9, 2016 according to StockzIntelligence Inc. The stock of Globus Medical Inc (NYSE:GMED) earned “Perform” rating by Oppenheimer on Wednesday, November 9. JMP Securities downgraded Globus Medical Inc (NYSE:GMED) on Wednesday, November 9 to “Mkt Perform” rating.

About 120,447 shares traded hands. Globus Medical Inc (GMED) has declined 15.85% since April 27, 2016 and is downtrending. It has underperformed by 21.08% the S&P500.

Analysts await Globus Medical Inc (NYSE:GMED) to report earnings on February, 22. They expect $0.33 earnings per share, up 3.13% or $0.01 from last year’s $0.32 per share. GMED’s profit will be $31.74M for 16.46 P/E if the $0.33 EPS becomes a reality. After $0.29 actual earnings per share reported by Globus Medical Inc for the previous quarter, Wall Street now forecasts 13.79% EPS growth.

Insitutional Activity: The institutional sentiment decreased to 0.88 in 2016 Q2. Its down 0.33, from 1.21 in 2016Q1. The ratio worsened, as 21 funds sold all Globus Medical Inc shares owned while 61 reduced positions. 25 funds bought stakes while 74 increased positions. They now own 65.87 million shares or 1.65% less from 66.98 million shares in 2016Q1.

Fiera Cap owns 373,623 shares or 0.05% of their US portfolio. Renaissance Tech Limited holds 0% or 104,700 shares in its portfolio. Ladenburg Thalmann Service holds 0% or 3,811 shares in its portfolio. Fifth Third Bank has invested 0.01% of its portfolio in Globus Medical Inc (NYSE:GMED). Timessquare Cap Mgmt Lc holds 1.92M shares or 0.3% of its portfolio. The Minnesota-based Ameriprise Financial has invested 0.02% in Globus Medical Inc (NYSE:GMED). Clinton Gp holds 0.09% or 90,504 shares in its portfolio. Falcon Point Capital Ltd Liability Co has 2.02% invested in the company for 489,734 shares. Bnp Paribas Arbitrage accumulated 0% or 4,852 shares. Invesco Limited, a Georgia-based fund reported 1.62M shares. Cap Impact Advisors Lc holds 0.44% of its portfolio in Globus Medical Inc (NYSE:GMED) for 39,626 shares. First Interstate State Bank has 540 shares for 0% of their US portfolio. The New York-based Jpmorgan Chase & Co has invested 0% in Globus Medical Inc (NYSE:GMED). Ahl Ptnrs Ltd Liability Partnership holds 0.26% of its portfolio in Globus Medical Inc (NYSE:GMED) for 199,725 shares. Farmers & Merchants, a Nebraska-based fund reported 248 shares.

Globus Medical, Inc. is a medical device company. The company has a market cap of $2.09 billion. The Firm is focused on developing products for patients with musculoskeletal disorders. It has a 17.8 P/E ratio. It is focused on products to treat patients with spine disorders.

According to Zacks Investment Research, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania.”

GMED Company Profile

Globus Medical, Inc., incorporated on March 3, 2003, is a medical device company. The Firm is focused on developing products for patients with musculoskeletal disorders. It is focused on products to treat patients with spine disorders. The Company’s products fall under categories, which include Innovative Fusion and Disruptive Technologies. The Innovative Fusion category products include fusion products to treat spinal disorders for the entire spine, and they can be used in various surgical approaches. The Disruptive Technologies category represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders.

More news for Globus Medical Inc (NYSE:GMED) were recently published by: Valuewalk.com, which released: “Globus Medical Inc (GMED)’s Inside Job” on March 22, 2016. Globenewswire.com‘s article titled: “Globus Medical Reports Third Quarter 2016 Results” and published on November 08, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>